Rep. Gilbert Ray Cisneros Jr. (D-CA) Sells BSX Stock

Representative Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, sold shares of Boston Scientific Corporation (BSX) on June 5, 2026. The transaction was valued between $1,001 and $15,000. The sale was reported on July 2, 2026.

Boston Scientific develops and sells medical devices used in various medical fields. The stock was recently priced at $44.12, which is near its 52-week low of $41.39. This suggests that the shares are under pressure, which could impact investor sentiment.

Other Institutional Activity in Boston Scientific

Blackrock Inc. reduced its holdings by 2,135,425 shares, ending with 129,680,916 shares valued at about $5.73 billion. Vanguard Capital Management LLC increased its position by 674,889 shares, bringing its total to 97,087,553 shares worth approximately $4.29 billion. State Street Corporation added 2,121,285 shares, totaling 70,111,196 shares valued at about $3.10 billion. Primecap Management Company significantly boosted its stake by 17,991,834 shares, now holding 50,520,914 shares worth around $2.23 billion. In contrast, FMR, LLC trimmed its position by 28,526,236 shares, leaving it with 45,702,845 shares valued at about $2.02 billion.

Boston Scientific Corporation Stock Up 2.6%

Boston Scientific shares are currently trading around $44.12, close to their 52-week low of $41.39. This low price point may attract some investors looking for value, but it also reflects current market challenges. The stock has a P/E ratio of 17.87, indicating how much investors are willing to pay for each dollar of earnings.

Recent Earnings

Boston Scientific reported revenue of about $20.99 billion, with a revenue growth rate of 7.5%. The company has an EPS of $2.47 and a net margin of 17.5%. The next earnings report is scheduled for October 28, 2026.

Insider Buying and Selling at Boston Scientific Corporation

On August 3, 2026, CEO Michael F. Mahoney bought 186,240 shares at an average price of $48.33, totaling about $9.00 million. Director David C. Habiger purchased 2,100 shares on August 5, 2026, at $47.59, valued at approximately $99,937. He also bought 1,182 shares on August 4, 2026, for about $56,887. Director Susan E. Morano bought 2,040 shares on August 25, 2026, averaging $49.22, totaling around $100,408.

Analysts Set New Price Targets

On October 14, 2026, Truist Securities maintained a "Buy" rating for Boston Scientific with a price target of $51.00, down from $57.00. Barclays initiated coverage with an "Equal-Weight" rating and a target of $48.00 on October 7, 2026. Citigroup maintained a "Neutral" rating with a $48.00 target on October 5, 2026, while Wells Fargo also kept an "Equal-Weight" rating at the same target. Oppenheimer maintained an "Outperform" rating with a target of $65.00 on September 21, 2026.

About Boston Scientific

Boston Scientific Corporation is a medical device company based in Marlborough, MA. It focuses on developing and marketing devices used in various medical specialties, including cardiology and surgical procedures. This recent sale by Rep. Cisneros highlights the ongoing financial activities surrounding the company, particularly as it operates in a sector that is crucial for healthcare advancements.

Bottom Line

Investors should keep an eye on the upcoming earnings report on October 28, 2026, as well as any further insider transactions. Remember, this sale by Rep. Cisneros is based on a report filed under the STOCK Act, reflecting his financial activities as of June 5, 2026.